Researchers published in Nature Communications that engineered vesicles can increase oral antibiotic absorption while protecting the gut microbiome, reporting both improved drug bioavailability and reduced dysbiosis in preclinical models. The work outlines a delivery vehicle that concentrates antibiotics at absorption sites and mitigates collateral microbial damage. If translated to humans, the approach could reduce systemic dosing requirements and lower rates of antibiotic‑associated microbiome disruption, with implications for stewardship, oral drug design, and commercial antibiotic pipelines.